EE197 Cost-Effectiveness Analysis of Trastuzumab Emtansine Versus Pertuzumab with Trastuzumab for Chinese Patients with Residual Invasive HER2-Positive Early Breast Cancer
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.446
https://www.valueinhealthjournal.com/article/S1098-3015(22)00647-7/fulltext
Title :
EE197 Cost-Effectiveness Analysis of Trastuzumab Emtansine Versus Pertuzumab with Trastuzumab for Chinese Patients with Residual Invasive HER2-Positive Early Breast Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00647-7&doi=10.1016/j.jval.2022.04.446
First page :
Section Title :
Open access? :
No
Section Order :
10394